Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood
; 143(7): 597-603, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048552
2.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506339
3.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356463
4.
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Blood
; 138(17): 1583-1589, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34133718
5.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102598
6.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031761
7.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood
; 135(26): 2375-2387, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299093
8.
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Br J Haematol
; 192(3): 522-530, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32501528
9.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Blood
; 134(16): 1337-1345, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31484647
10.
Increasing therapy-related myeloid neoplasms in multiple myeloma.
Eur J Clin Invest
; 49(2): e13050, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30422316
11.
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Blood
; 127(9): 1151-62, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26668134
12.
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Blood
; 127(15): 1896-906, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755711
13.
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Blood
; 128(4): 497-503, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27226434
14.
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Blood
; 126(7): 858-62, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26089396
15.
Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.
Eur J Haematol
; 98(2): 142-148, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717146
16.
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(8): 1127-1136, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27402145
17.
Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations.
Br J Haematol
; 172(6): 937-46, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26728704
18.
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
N Engl J Med
; 369(5): 438-47, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23902483
19.
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Blood
; 124(12): 1887-93, 2014 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25102853
20.
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Ann Hematol
; 95(12): 2033-2041, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27738789